Long-term efficacy and safety outcomes after unrestricted use of drug-eluting stents in patients with acute coronary syndrome - Mortality and major bleeding in a single-center registry

Circulation Journal

Volumn 78, Issue 7, 2014, Pages 1628-1635

  Kawaji, Tetsuma ^a   Shiomi, Hiroki ^a   Morimoto, Takeshi ^b   Tamura, Toshihiro ^c   Nishikawa, Ryusuke ^a   Yano, Mariko ^a   Tazaki, Junichi ^a   Imai, Masao ^a   Saito, Naritatsu ^a   Makiyama, Takeru ^a   Shizuta, Satoshi ^a   Ono, Koh ^a   Kimura, Takeshi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c TENRI HOSPITAL   (Japan)

Author keywords

Acute coronary syndrome; Bleeding; Drug eluting stents

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLEEDING; CLINICAL EVALUATION; CORONARY ARTERY RECANALIZATION; DEVICE SAFETY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; QUANTITATIVE ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 84903194925     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1388     Document Type: Article

References (23)

1. Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012; 380: 1482-1490.
2. Raber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tuller D, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: The COMFORTABLE AMI randomized trial. JAMA 2012; 308: 777-787.
3. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 2013; 82: E1-E27, doi:10.1002/ccd.24776.
4. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-1124.
5. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
6. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
7. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093-1104.
8. Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, et al. Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction (SESAMI). J Am Coll Cardiol 2007; 49: 1924-1930.
9. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, et al. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007; 370: 937-948.
10. Ejiri K, Ishihara M, Dai K, Miki T, Inoue I, Kawagoe T, et al. Threeyear follow-up of sirolimus-eluting stents vs. bare metal stents for acute myocardial infarction. Circ J 2012; 76: 65-70.
11. Kalesan B, Pilgrim T, Heinimann K, Raber L, Stefanini GG, Valgimigli M, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eurn Heart J 2012; 33: 977-987.
12. Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Iwabuchi M, et al. Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan. Cardiovasc Interv Ther 2011; 26: 234-245.
13. Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: A prospective, multicenter, observational study. Stroke 2008; 39: 1740-1745.
14. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782.
15. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 2009; 119: 1873-1882.
16. Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, et al. Bleeding in patients undergoing percutaneous coronary intervention: The development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovas Interv 2009; 2: 222-229.
17. Moukarbel GV, Signorovitch JE, Pfeffer MA, McMurray JJ, White HD, Maggioni AP, et al. Gastrointestinal bleeding in high risk survivors of myocardial infarction: The VALIANT Trial. Eur Heart J 2009; 30: 2226-2232.
18. Manoukian SV. Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. Am J Cardiol 2009; 104: 9C-15C.
19. Mehran R, Pocock S, Nikolsky E, Dangas GD, Clayton T, Claessen BE, et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv 2011; 4: 654-664.
20. Suh JW, Mehran R, Claessen BE, Xu K, Baber U, Dangas G, et al. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 2011; 58: 1750-1756.
21. Chitose T, Hokimoto S, Oshima S, Nakao K, Fujimoto K, Miyao Y, et al. Clinical Outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor. Circ J 2012; 76: 71-78.
22. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al. Antiplatelet therapy and stent thrombosis after sirolimuseluting stent implantation. Circulation 2009; 119: 987-995.
23. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation 2006; 113: 2803-2809.